Literature DB >> 9521133

Evaluation of an immunoglobulin G enzyme-linked immunosorbent assay for pertussis toxin and filamentous hemagglutinin in diagnosis of pertussis in Senegal.

F Simondon1, I Iteman, M P Preziosi, A Yam, N Guiso.   

Abstract

The enzyme-linked immunosorbent assay is widely employed for the serological diagnosis of pertussis. It is generally concluded that a significant increase in specific immunoglobulin G (IgG) or IgA against the pertussis toxin (PT) or against filamentous hemagglutinin (FHA) in paired sera correlates with Bordetella pertussis infection. However, this type of diagnosis of pertussis has mainly been applied to unvaccinated children, with timely sampling of acute- and convalescent-phase sera. In current practice and in epidemiological studies, such criteria are not always fulfilled. The aim of this study was to analyze the significance of decreases in IgG antibody titers against PT and FHA between paired sera observed in suspected cases of pertussis infection. Serological results from paired sera were available for 460 children experiencing at least 8 days of cough. An anti-PT IgG decrease was observed in 25% of the children, more frequently than the anti-FHA IgG decrease. Fourteen percent of the serologic decreases were observed in children with culture-confirmed infection, and 59% of the decreases were observed in children with confirmation criteria according to World Health Organization recommendations. Most of the decreases were observed when serum samples were collected according to a standard recommended schedule. Serologic decreases were observed more frequently among vaccinated children than among unvaccinated children. This difference, which was highly significant (P < 0.00001), was explained by the different kinetics of the antibody responses between vaccinated and unvaccinated children. The importance of the antibody response for the evaluation of vaccine efficacy, namely a bias toward higher absolute vaccine efficacy when this response is not taken into account, is discussed. This study supports an earlier recommendation that a significant decrease in PT or FHA should be added to the diagnostic criteria for pertussis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9521133      PMCID: PMC121348          DOI: 10.1128/CDLI.5.2.130-134.1998

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  11 in total

1.  Changes in immunity and antitoxin level immediately after secondary stimulus with tetanus toxoid in rabbits.

Authors:  J IPSEN
Journal:  J Immunol       Date:  1961-01       Impact factor: 5.422

2.  Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial.

Authors:  J Storsaeter; H Hallander; C P Farrington; P Olin; R Möllby; E Miller
Journal:  Vaccine       Date:  1990-10       Impact factor: 3.641

3.  Evaluation of serologic assays for diagnosis of whooping cough.

Authors:  G Granström; B Wretlind; C R Salenstedt; M Granström
Journal:  J Clin Microbiol       Date:  1988-09       Impact factor: 5.948

4.  Comparative safety and immunogenicity of an acellular versus whole-cell pertussis component of diphtheria-tetanus-pertussis vaccines in Senegalese infants.

Authors:  F Simondon; A Yam; J Y Gagnepain; S Wassilak; B Danve; M Cadoz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-12       Impact factor: 3.267

5.  Collaborative study for the evaluation of enzyme-linked immunosorbent assays used to measure human antibodies to Bordetella pertussis antigens.

Authors:  F Lynn; G F Reed; B D Meade
Journal:  Clin Diagn Lab Immunol       Date:  1996-11

6.  Response and decline of serum IgG antibodies to pertussis toxin, filamentous hemagglutinin and pertactin in children with pertussis.

Authors:  J Isacson; B Trollfors; G Hedvall; J Taranger; G Zackrisson
Journal:  Scand J Infect Dis       Date:  1995

7.  No evidence of long-term immunosuppression after high-titer Edmonstron-Zagreb measles vaccination in Senegal.

Authors:  B Samb; H Whittle; P Aaby; A M Seck; J Bennett; L Markowitz; P T Ngom; H Zeller; K F Michaelsen; F Simondon
Journal:  J Infect Dis       Date:  1995-02       Impact factor: 5.226

8.  Serologic diagnosis of pertussis: comparison of enzyme-linked immunosorbent assay and bacterial agglutination.

Authors:  J Mertsola; O Ruuskanen; T Kuronen; M K Viljanen
Journal:  J Infect Dis       Date:  1983-02       Impact factor: 5.226

9.  Evaluation of serology and nasopharyngeal cultures for diagnosis of pertussis in a vaccine efficacy trial.

Authors:  H O Hallander; J Storsaeter; R Möllby
Journal:  J Infect Dis       Date:  1991-05       Impact factor: 5.226

10.  A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal.

Authors:  F Simondon; M P Preziosi; A Yam; C T Kane; L Chabirand; I Iteman; G Sanden; S Mboup; A Hoffenbach; K Knudsen; N Guiso; S Wassilak; M Cadoz
Journal:  Vaccine       Date:  1997-10       Impact factor: 3.641

View more
  12 in total

1.  Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis.

Authors:  James D Cherry; Ulrich Heininger; David M Richards; Jann Storsaeter; Lennart Gustafsson; Margaretha Ljungman; Hans O Hallander
Journal:  Clin Vaccine Immunol       Date:  2010-03-24

Review 2.  Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies.

Authors:  Seema Mattoo; James D Cherry
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

Review 3.  Laboratory Diagnosis of Pertussis.

Authors:  Anneke van der Zee; Joop F P Schellekens; Frits R Mooi
Journal:  Clin Microbiol Rev       Date:  2015-10       Impact factor: 26.132

4.  Two-component cluster analysis of a large serodiagnostic database for specificity of increases of IgG antibodies against pertussis toxin in paired serum samples and of absolute values in single serum samples.

Authors:  Sabine C de Greeff; Peter Teunis; Hester E de Melker; Frits R Mooi; Daan W Notermans; Bert Elvers; Joop F P Schellekens
Journal:  Clin Vaccine Immunol       Date:  2012-07-11

5.  Comparison of serological and real-time PCR assays to diagnose Bordetella pertussis infection in 2007.

Authors:  Philippe André; Valerie Caro; Elisabeth Njamkepo; Aaron M Wendelboe; Annelies Van Rie; Nicole Guiso
Journal:  J Clin Microbiol       Date:  2008-03-26       Impact factor: 5.948

6.  Seroprevalence of pertussis in Senegal: a prospective study.

Authors:  Lobna Gaayeb; Jean Biram Sarr; Mamadou O Ndiath; Jean-Baptiste Hanon; Anne-Sophie Debrie; Modou Seck; Anne-Marie Schacht; Franck Remoué; Emmanuel Hermann; Gilles Riveau
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

7.  Pertussis vaccine: a critique.

Authors:  John B Robbins; Rachel Schneerson; Jerry M Keith; Mark A Miller; Joanna Kubler-Kielb; Birger Trollfors
Journal:  Pediatr Infect Dis J       Date:  2009-03       Impact factor: 2.129

8.  Whole-cell pertussis vaccine induces low antibody levels in human immunodeficiency virus-infected children living in sub-Saharan Africa.

Authors:  Mathurin C Tejiokem; Elisabeth Njamkepo; Ionela Gouandjika; Dominique Rousset; Lydie Béniguel; Catherine Bilong; Gilbert Tene; Ida Penda; Carine Ngongueu; Jean C Gody; Nicole Guiso; Laurence Baril
Journal:  Clin Vaccine Immunol       Date:  2009-02-04

Review 9.  What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories.

Authors:  N Guiso; G Berbers; N K Fry; Q He; M Riffelmann; C H Wirsing von König
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-11-11       Impact factor: 3.267

10.  Sensitivity and specificity of single IgA and IgG antibody concentrations for early diagnosis of pertussis in adults: an evaluation for outbreak management in public health practice.

Authors:  Paul L J M Mertens; Frans S Stals; Ewout W Steyerberg; Jan H Richardus
Journal:  BMC Infect Dis       Date:  2007-06-06       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.